Artificial intelligence (AI) firm Elucid is highlighting results from a clinical study that support the effectiveness of its cardiovascular disease detection software.
The study was published January 30 in the International Journal of Cardiology and shows that Elucid's AI software can quantify vessel structure and plaque composition using data from a routine CT angiography (CTA), according to the firm.
A team led by Dr. Akos Varga-Szemes and Dr. Joseph Schoepf of the Medical University of South Carolina conducted the research.
